PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19

2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV Bladder Cancer

Published: Mar 06, 2020 | Tags: AstraZeneca, Reports, Results, Imfinzi, Tremelimumab, P-III, DANUBE, Study, Unresectable, Stage IV, Bladder Cancer

3. Allergan’s Durysta (bimatoprost implant) Receives the US FDA’s Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Published: Mar 05, 2020 | Tags: Allergan, Durysta, bimatoprost implant, Receives, US, FDA, Approval, First, Intracameral, Biodegradable, Sustained-Release Implant, Patients, OAG, OHT

4. Zydus’ Saroglitazar Receives DCGI’s Approval as the World’s First Therapy for Non-Cirrhotic NASH in India

Published: Mar 05, 2020 | Tags: Zydus, Saroglitazar, Receives, DCGI, Approval, World, First Therapy, Non-Cirrhotic, NASH, India

5. Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

Published: Mar 05, 2020 | Tags: Novartis, Enters, Four-Year, Collaboration, Orionis Biosciences, Tackle, Intractable, Disease Targets

6. The US FDA Informs About Cybersecurity Vulnerabilities in Medical Devices with Bluetooth Low Energy

Published: Mar 04, 2020 | Tags: US, FDA, Informs, About, Cybersecurity Vulnerabilities, Medical Devices, Bluetooth Low Energy

7. Heat Biologics Signs a Research Collaboration with University of Miami to Develop Vaccine Against COVID-19

Published: Mar 05, 2020 | Tags: Heat Biologics, Signs, Research Collaboration, University of Miami, Develop, Vaccine, Against, COVID-19

8. Zuellig Pharma Acquires Alliance Pharma (Cambodge) to Bolster its Presence in Indochina

Published: Mar 05, 2020 | Tags: Zuellig Pharma, Acquires, Alliance Pharma, Cambodge, Bolster, Presence, Indochina

9. Roche’s Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China

Published: Mar 04, 2020 | Tags: Roche, Actemra, tocilizumab, Receives, Approval, Combat, Coronavirus Complications, China

10. Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Published: Mar 04, 2020 | Tags: Alopexx, Signs, Exclusive, License Agreement, Beijing Shenogen Pharma, Develop, Commercialize, DI-LEU16-IL2, B-Cell Lymphomas, China, Asia

11. Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Published:  Mar 04, 2020 | Tags: Allergan, Editas, Report, First Patient Dosing, P-I/II, BRILLIANCE Study, AGN-151587, EDIT-101, Treat, LCA10

12. Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Published: Mar 04, 2020 | Tags: Vir, Alnylam, Expand, 2017, License Agreement, Target, COVID-19

13. Janssen Reports Submission of Ponesimod’s MAA to EMA for the Treatment of Relapsing Multiple Sclerosis

Published: Mar 04, 2020 | Tags: Janssen, Reports, Submission, MAA, EMA, Ponesimod, Treat, Patients, Relapsing Multiple Sclerosis

14. Iktos and SRI Collaborate to Accelerate Discovery and Development of Novel Anti-Viral Therapies

Published: Mar 03, 2020 | Tags: Iktos, SRI, Collaborate, Accelerate, Discovery, Development, Novel, Anti-Viral Therapies

15. Alnylam’s Givlaari (givosiran) Receives EC’s Approval for Acute Hepatic Porphyria in Adults and Adolescents

Published: Mar 03, 2020 | Tags: Alnylam, Givlaari, givosiran, Receives, EC, Approval, Acute Hepatic Porphyria, AHP, Adults, Adolescents

16. Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19)

Published: Mar 04, 2020 | Tags: Takeda, Initiate, Development, Plasma-Derived Therapy, Treat, Corona Virus, COVID-19

17. Roche’s Elecsys GALAD scores Receive the US FDA’s Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma

Published: Mar 03, 2020 | Tags: Roche, Elecsys GALAD scores, Receives, US, FDA, Breakthrough Device Designation, Earlier Diagnosis, Hepatocellular Carcinoma

18. BMS Collaborates with Voluntis to Co-Develop Digital Therapies to Treat Cancer Indications

Published: Mar 03, 2020 | Tags:  BMS, Collaborates, Voluntis, Co-Develop, Digital Therapies, Cancer

19. Novartis’ Mayzent Receives Health Canada’s Approval for Secondary Progressive Multiple Sclerosis with Active Disease

Published: Mar 03, 2020 | Tags: Novartis, Mayzent, Receives, Health Canada, Approval, Secondary Progressive Multiple Sclerosis, Active Disease

20. Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate EsoCheck in Patients with Eosinophilic Esophagitis

Published: Mar 02, 2020 | Tags: Lucid Diagnostics, Collaborates, University of Pennsylvania, Evaluate, EsoCheck, Patients, Eosinophilic Esophagitis

21.  Genentech’s Esbriet (pirfenidone) Receives FDA’s Breakthrough Therapy Designation for Unclassifiable Interstitial Lung Disease

Published: Mar 03, 2020 | Tags: Genentech, Esbriet, pirfenidone, Receives, FDA, Breakthrough Therapy Designation, Unclassifiable, Interstitial Lung Disease

22.  Insulet to Halt Study of Omnipod Horizon Due to Software Anomaly

Published: Mar 03, 2020 | Tags: Insulet, Discontinue, Study, Omnipod Horizon, Software Anomaly

23. Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Published: Mar 03, 2020 | Tags: Thermo Fisher Scientific, Acquire, QIAGEN, ~$11.5B

24. Sanofi’s Sarclisa (isatuximab-irfc) Receives the US FDA’s Approval for Relapsed Refractory Multiple Myeloma

Published: Mar 02, 2020 | Tags: Sanofi, Sarclisa, isatuximab-irfc, Receives, US, FDA, Approval, Relapsed Refractory Multiple Myeloma

25. uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

Published: Mar 02, 2020 | Tags: uniQure, Signs, Exclusive, Research, License Agreement, Gen-X, Develop, Novel Synthetic Promoters

26. Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Published: Mar 02, 2020 | Tags: Pfizer, Eli Lilly, Report, US, FDA, Acceptance, BLA, Tanezumab, Treat, Chronic Pain, Moderate-to-Severe, Osteoarthritis

27. Gilead to Acquire Forty Seven for $4.9B

Published: Mar 02, 2020 | Tags: Gilead, Acquire, Forty Seven, $4.9B

28. Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M

Published: Mar 02, 2020 | Tags: Takeda, Divest, Portfolio, Select OTC, Non-Core Assets, Hypera Pharma, Latin America, $825M

29. Medexus Acquires Aptevo BioTherapeutics for its Hematology Asset IXINITY

Published: Feb 28, 2020 | Tags: Medexus, Acquires, Aptevo BioTherapeutics, Hematology Asset, IXINITY

30. Boehringer Ingelheim’s Nintedanib Receives CHMP’s Positive Opinion to Treat Systemic Sclerosis-Associated Interstitial Lung Disease

Published: Feb 28, 2020 | Tags: Boehringer Ingelheim, Nintedanib, Receives, CHMP, Positive Opinion, Treat, Systemic Sclerosis-Associated Interstitial Lung Disease

31. Merck KGaA’s ERBITUX (cetuximab) Receives NMPA’s Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Published: Mar 02, 2020 Tags: Merck KGaA, ERBITUX, cetuximab, Receives, NMPA, Approval, 1L, Treatment, Recurrent/ Metastatic, Squamous Cell Carcinoma of Head and Neck